[A23-36] Cemiplimab (cervical cancer) – Benefit assessment according to §35a Social Code Book V
Last updated 01.08.2023
Project no.: A23-36
Commission: Commission awarded on 24.04.2023 by the Federal Joint Committee (G-BA).
Report type: Dossier assessment
Status: Commission completed
Department/Division: Drug Assessment
Topic: Cancer
Indication:
Adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.